Mesocaïne (Lidocaine Hydrochloride)

Lidocaine Hydrochloride is used in clinical settings that require rapid local anesthesia or cardiac rhythm control.

• Local anesthesia for minor surgical or diagnostic procedures: provides rapid onset numbing of targeted tissue.
• Management of ventricular arrhythmias: stabilizes cardiac electrical activity during acute episodes.
• Treatment of acute pain during surgery or postoperative period: reduces pain perception when administered intravenously.

• Lidocaine blocks voltage‑gated sodium channels on neuronal and cardiac cell membranes, preventing the rapid influx of sodium ions that initiates and propagates action potentials. This inhibition reduces nerve impulse transmission and stabilizes cardiac excitability, leading to loss of sensation in the targeted area and suppression of abnormal cardiac rhythms.

Lidocaine may cause a range of adverse reactions, from mild to severe, depending on dose, route, and patient factors.

Common Side Effects

• Tingling or numbness at the injection site
• Dizziness or light‑headedness
• Nausea or vomiting
• Metallic taste in the mouth
• Mild hypotension
• Transient visual disturbances

Serious or Rare Side Effects

• Seizures or convulsions
• Cardiac arrest or severe bradycardia
• Anaphylactic or severe allergic reactions
• Methemoglobinemia
• Respiratory depression
• Persistent arrhythmias

When using Mesocaïne, clinicians should observe several safety measures.

• Cardiac assessment: evaluate baseline ECG and cardiac history before administration.
• Hepatic function: adjust dosing in patients with significant liver impairment.
• Hypersensitivity: avoid use in individuals with known lidocaine allergy.
• Concomitant drugs: monitor closely when combined with other sodium channel blockers.
• Dosage monitoring: observe for signs of systemic toxicity during infusion.
• Store at ambient temperature: keep in the original container, protect from light and moisture.

Lidocaine can interact with other medications, altering its efficacy or safety profile.

Major Interactions (Avoid)

• Class I antiarrhythmics (e.g., quinidine, procainamide): additive cardiac toxicity.
• CYP3A4 inhibitors (e.g., ketoconazole, erythromycin): increase lidocaine plasma levels.
• Beta‑adrenergic blockers (e.g., propranolol): may exacerbate bradycardia and hypotension.

Moderate Interactions (Monitor Closely)

• CYP1A2 inducers (e.g., rifampin): may lower lidocaine concentrations.
• Other local anesthetics (e.g., bupivacaine): risk of cumulative systemic toxicity.